Moderna to Request FDA Authorization of a COVID-19 Vaccine for Children 6 months to Under 6 years

The request is based on interim data from the Phase 2/3 KidCOVE study of a 25 µg two-dose mRNA vaccine.

Moderna found that these doses “showed a robust neutralizing antibody response” similar to adults’ doses, with a “favorable safety profile.”

Click here to learn more.

This website is supported by the Centers for Disease Control and Prevention of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award totaling $950,000 with 100 percent funded by CDC/HHS. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by CDC/HHS, or the U.S. Government. Privacy Policy | Disclaimer